Literature DB >> 11520151

Identification of prognostic factors in advanced epithelial ovarian carcinoma.

D S Chi1, J B Liao, L F Leon, E S Venkatraman, M L Hensley, D Bhaskaran, W J Hoskins.   

Abstract

OBJECTIVE: The Gynecologic Oncology Group (GOG) has demonstrated that age, tumor grade, and size and number of residual lesions after primary cytoreductive surgery are significant prognostic factors in advanced ovarian carcinoma. Recent studies have reported numerous other clinical features as having prognostic value. We sought to identify the independent prognostic factors for survival in a cohort of patients with advanced ovarian cancer.
METHODS: We performed a retrospective chart review of all patients with stage III and IV ovarian carcinoma who received their primary treatment at our institution between 1987 and 1994.
RESULTS: A total of 295 patients were identified, 282 of whom were evaluable. Of these 282 patients, 214 (76%) have died of disease or other causes. The median follow-up is 32 months (range: 1-139). Eighteen factors were evaluated for prognostic significance. Significant factors in univariate analysis included patient age, gravidity (0 vs > 0), parity (0 vs > 0), preoperative albumin level, preoperative total protein level, ascites (presence vs absence), disease stage (IIIA/IIIB vs IIIC vs IV), number of residual lesions (< or =20 vs >20), and diameter of largest residual tumor nodule (< or = 1 cm vs 1-2 cm vs > 2 cm). However, on multivariate analysis, only patient age (P < 0.001), ascites (P = 0.001), and size of residual disease (P = 0.005) retained prognostic significance. Substage of disease was of borderline significance (P = 0.086).
CONCLUSION: Although numerous clinical variables have recently been reported to have prognostic value in advanced ovarian carcinoma, only patient age, presence or absence of ascites, and diameter of the largest residual tumor nodule proved to be of statistical significance in our analysis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520151     DOI: 10.1006/gyno.2001.6328

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  40 in total

1.  The optimal time for surgery in women with serous ovarian cancer.

Authors:  Jocelyn M Stewart; Alicia A Tone; Haiyan Jiang; Marcus Q Bernardini; Sarah Ferguson; Stephane Laframboise; K Joan Murphy; Barry Rosen; Taymaa May
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

2.  A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer.

Authors:  Kimberly Fung; Sai Kiran Sharma; Outi Keinänen; Kara Long Roche; Jason S Lewis; Brian M Zeglis
Journal:  Mol Pharm       Date:  2020-07-16       Impact factor: 4.939

3.  Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer.

Authors:  C I Nagel; F J Backes; E M Hade; D E Cohn; E L Eisenhauer; D M O'Malley; J M Fowler; L J Copeland; R Salani
Journal:  Gynecol Oncol       Date:  2011-11-04       Impact factor: 5.482

4.  Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Irene A Burger; Debra A Goldman; Hebert Alberto Vargas; Michael W Kattan; Changhon Yu; Lei Kou; Vaagn Andikyan; Dennis S Chi; Hedvig Hricak; Evis Sala
Journal:  Gynecol Oncol       Date:  2015-06-17       Impact factor: 5.482

5.  Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer.

Authors:  Dae Chul Jung; Sokbom Kang; Min Ju Kim; Sang Yoon Park; Hyun Beom Kim
Journal:  Eur Radiol       Date:  2009-08-06       Impact factor: 5.315

6.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Svetlana Mironov; Revathy B Iyer; Qin Zhou; Alexia Iasonos; Harold Paul; Masayoshi Hosaka; Carol A Aghajanian; Mario M Leitao; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2014-07-11       Impact factor: 5.482

7.  Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Authors:  C A Hamilton; A Miller; Y Casablanca; N S Horowitz; B Rungruang; T C Krivak; S D Richard; N Rodriguez; M J Birrer; F J Backes; M A Geller; M Quinn; M J Goodheart; D G Mutch; J J Kavanagh; G L Maxwell; M A Bookman
Journal:  Gynecol Oncol       Date:  2017-11-28       Impact factor: 5.482

8.  Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.

Authors:  Thomas Boerner; Olga T Filippova; Andrew J Chi; Alexia Iasonos; Qin C Zhou; Kara Long Roche; Oliver Zivanovic; Bernard J Park; James Huang; David R Jones; Nadeem R Abu-Rustum; Ginger Gardner; Yukio Sonoda; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2020-08-10       Impact factor: 5.482

9.  Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness.

Authors:  Elizabeth M Poole; Melissa A Merritt; Susan J Jordan; Hannah P Yang; Susan E Hankinson; Yikung Park; Bernard Rosner; Penelope M Webb; Daniel W Cramer; Nicolas Wentzensen; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-10       Impact factor: 4.254

10.  Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy.

Authors:  Jean-Luc Brun; Roman Rouzier; Frédéric Selle; Sidney Houry; Serge Uzan; Emile Daraï
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.